GENFIT Highlights ACLF Research at EASL Congress 2025

Genfit SA ( (GNFT) ) just unveiled an announcement.

On May 5, 2025, GENFIT announced its participation in the European Association for the Study of the Liver (EASL) Annual Congress 2025, showcasing six posters on ACLF research and hosting multiple events to emphasize the significance of ACLF in hepatology. The company’s involvement includes presenting real-world data, discussing AI tools in drug development, and collaborating with the European Foundation for the Study of Chronic Liver Failure to enhance patient care and research initiatives. These efforts highlight GENFIT’s strategic focus on ACLF, aiming to foster collaboration and improve treatment outcomes for liver disease patients.

Spark’s Take on GNFT Stock

According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.

Genfit SA’s overall stock score is driven by its strong financial recovery and positive technical indicators, indicating a favorable trajectory. However, the high P/E ratio suggests an overvaluation risk, which could impact investor sentiment if growth expectations are not met. The absence of earnings call insights limits the assessment of future guidance and sentiment.

To see Spark’s full report on GNFT stock, click here.

More about Genfit SA

GENFIT S.A. is a biopharmaceutical company focused on developing therapeutic and diagnostic solutions for patients with rare and life-threatening liver diseases. The company is actively involved in research and development, particularly in the area of Acute-on-Chronic Liver Failure (ACLF), and is committed to advancing scientific understanding and treatment options within the hepatology community.

YTD Price Performance: 11.70%

Average Trading Volume: 12,634

Technical Sentiment Signal: Sell

Current Market Cap: $213.2M

For detailed information about GNFT stock, go to TipRanks’ Stock Analysis page.